Listen to this article · 8 min listen

The hype around AI in healthcare is real, but the race to adopt clinical AI solutions is creating a minefield of liability. These risks are shifting away from individual doctors and landing squarely on the digital health developers and, more importantly, their investors. For venture capital risk managers and digital health board members, this report is a field guide for identifying and defusing the top clinical AI safety risks inside your portfolio companies before they blow up.

The Shifting Sands of AI Liability: From Provider to Investor

Medical malpractice claims have always focused on a clinician’s screw-up. That’s changing. As AI-powered Software as a Medical Device (SaMD) gets baked into how we diagnose and treat patients, the law is catching up. When an algorithm fails, because of biased training data, model drift over time, or just sloppy validation, it can hurt a patient directly. And when that happens, the legal spotlight hits the developers who wrote the code and the VCs who funded its release. Because of this new liability model, investors have to get serious about clinical AI safety themselves. You can’t just assume the startup’s team has it covered. The FDA’s evolving stance on Clinical Decision Support (CDS) Software shows just how fast this is moving. Some simple CDS tools may fly under the regulatory radar, but anything that actually influences a diagnosis or treatment plan is getting treated like a medical device. This matters to investors. A product you thought was an unregulated CDS tool could easily, after a few feature updates or a change in how it’s used, become a regulated device that needs a full 510(k) clearance or even a De Novo classification, completely derailing your risk profile and go-to-market timeline. FDA guidance on Clinical Decision Support Software

Identifying Top Clinical AI Hazards: Lessons from ECRI and Litigation Trends

To see where the real dangers are in clinical AI, you have to look at what the experts are flagging and what’s actually leading to lawsuits. The ECRI Institute, an independent authority on med-tech safety, consistently calls out AI-related risks in its annual “Top 10 Health Technology Hazards” report. For example, the 2026 report named the “Misuse of AI chatbots in healthcare” a top hazard, just after the 2025 report put “Risks with AI-enabled health technologies” in the number one spot. You also see recurring themes like “Ransomware and other cybersecurity threats” and “Cybersecurity risks from legacy medical devices,” which become AI problems the second these systems get connected to hospital networks. ECRI is also sounding the alarm on hazards from AI-driven diagnostic mistakes and algorithmic bias that creates health inequities. It’s not just foresight from ECRI, either. Real lawsuits involving algorithmic misdiagnosis are piling up and serving as a warning. Though many of these cases are settled out of court and sealed, the number of legal challenges over poor AI performance is growing. We’re already seeing lawsuits where AI algorithms are accused of wrongly denying post-acute care to Medicare Advantage members, and others where AI chatbots gave out advice that allegedly delayed a patient from seeking real care. These cases usually depend on proving a straight line from the AI’s output to the patient’s injury, which puts a huge premium on having rock-solid validation data and transparency for your models. The American Medical Association (AMA) is also weighing in, pushing for physician-led AI governance and ethical AI development. Their policies keep hammering on the need for transparent, accountable, and well-tested AI, building a consensus that these tools are there to help a doctor’s judgment, not take its place. AMA policy on AI in healthcare

A Checklist for Investors: Auditing Clinical Safety Protocols

With these risks evolving so quickly, VC firms and board members need to build a full clinical AI safety audit into due diligence and ongoing governance. This checklist offers a framework to get started:

  • Regulatory Compliance and Pathway Clarity:
    • Is this thing a medical device (SaMD) or not? What’s the regulatory path, 510(k), De Novo, or Breakthrough Device Designation? You need a clear answer.
    • Has the team actually talked to the FDA (or the EU bodies for CE Mark/MDR) early on? Or are they just hoping for the best?
    • For adaptive AI/ML models, is there a Predetermined Change Control Plan (PCCP) so the algorithm can be updated without going back to the FDA every single time it learns something new?
  • Data Integrity and Bias Mitigation:
    • Where did the training data come from and is it representative of the real world? Is there a baked-in bias that will cause it to fail for certain patient groups, opening you up to both safety and equity lawsuits?
    • How are you checking for algorithmic drift once it’s live? What’s the process for continuous learning and retraining the model before its performance degrades?
    • Show me the data governance policies. Do you have HIPAA compliance, a HITRUST certification, or SOC 2 Type II reports? We need to know data is secure and private.
  • Validation and Performance Monitoring:
    • How good is the clinical evidence? Is it all based on looking backwards at old data, or are there actual prospective studies or plans to generate Real-World Evidence (RWE)?
    • How does the company even define clinical utility? Is it clear what this AI is supposed to do in a real clinic and how it’s supposed to help?
    • Are post-market surveillance systems in place to watch the AI’s performance and catch safety problems as they happen, not after the fact?
  • Transparency and Explainability:
    • Can anyone explain why the model is making a certain recommendation? A “black box” AI is a huge liability because a clinician can’t properly supervise it. This explainability is what builds trust and enables proper clinical oversight.
    • Are the AI’s limitations spelled out for every user? Is the interface designed to prevent people from blindly trusting it or using it for things it wasn’t built for?
  • Quality Management Systems (QMS) and Good Machine Learning Practice (GMLP):
    • Does the company operate under an ISO 13485-certified QMS? This shows a disciplined process for design, development, and post-market activities. It’s not optional for serious med-tech.
    • Are the principles of Good Machine Learning Practice (GMLP) actually being followed through the whole development cycle, from gathering data to deploying and monitoring the model? FDA/Health Canada/MHRA Good Machine Learning Practice guidance
  • Clinical Integration and Human Oversight:
    • How does this tool fit into a doctor’s actual day? Is it a nightmare to use or does it genuinely help?
    • Does it augment human decision-making, not replace it? There must be clear ways for a clinician to review and override the AI’s output, especially in high-stakes situations.
    • What kind of training do end-users (the doctors and nurses) get? How do you make sure they can use the AI safely and correctly?

Walking through this checklist gives you a real sense of a company’s safety culture, helps you spot hidden “regulatory debt” that will come due later, and lets you fix problems before they end up in a courtroom.

Methodology and Source Note

This report pulls together information from the most credible sources in med-tech and regulation. Our main inputs are the yearly “Top 10 Health Technology Hazards” reports from the ECRI Institute, which give an unbiased, evidence-based view on what’s going wrong in medical technology. We also incorporated policy statements from the American Medical Association (AMA) on the ethical use of AI in medicine, along with final guidance from the U.S. Food and Drug Administration (FDA) on CDS software and AI/ML devices. Combining these sources gives a complete and practical framework for dealing with the headaches of clinical AI safety and liability.

Frequently Asked Questions

How is liability for clinical AI shifting, and what does this mean for investors?

Liability for clinical AI is shifting from individual providers to digital health developers and their investors. This means investors are increasingly exposed to risks from algorithmic failures, biased training data, or inadequate validation that can cause patient harm. This necessitates a rigorous, investor-centric approach to clinical AI safety.

What are the primary clinical AI hazards identified by experts and litigation trends?

Top hazards include algorithmic bias leading to health inequities, diagnostic errors, and misuse of AI chatbots. Litigation trends show increasing cases alleging AI algorithms wrongfully denied care or provided harmful medical guidance. These highlight the need for robust validation and transparency in AI models.

What regulatory considerations are critical for investors in clinical AI companies?

Investors must understand if an AI product is a Software as a Medical Device (SaMD) and its regulatory pathway (e.g., 510(k), De Novo). Products initially conceived as unregulated Clinical Decision Support (CDS) could become regulated devices through feature expansion, significantly altering risk and time-to-market. Early engagement with regulatory bodies like the FDA is crucial.

What key areas should investors audit regarding a clinical AI company’s safety protocols?

Investors should audit regulatory compliance and pathway clarity, data integrity and bias mitigation, and validation and performance monitoring. This includes assessing the provenance of training data, mechanisms for monitoring algorithmic drift, and the quality of clinical evidence supporting the AI’s efficacy. Robust data governance and continuous learning plans are also essential.